CAPOTEN Drug Patent Profile

When do Capoten patents expire, and when can generic versions of Capoten launch?

Capoten is a drug marketed by Aarxion Anda Hlding and is included in one NDA.

The generic ingredient in CAPOTEN is captopril. There are fifteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the captopril profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Capoten

A generic version of CAPOTEN was approved as captopril by HIKMA INTL PHARMS on February 13^th, 1996.

Summary for CAPOTEN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	118
Clinical Trials:	5
DailyMed Link:	CAPOTEN at DailyMed

Recent Clinical Trials for CAPOTEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	Phase 1
Children's Cancer Hospital Egypt 57357	Phase 3
University of Nebraska	Phase 4

See all CAPOTEN clinical trials

US Patents and Regulatory Information for CAPOTEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aarxion Anda Hlding	CAPOTEN	captopril	TABLET;ORAL	018343-005	Jan 17, 1985		DISCN	Yes	No
Aarxion Anda Hlding	CAPOTEN	captopril	TABLET;ORAL	018343-004	Jun 13, 1995		DISCN	Yes	No
Aarxion Anda Hlding	CAPOTEN	captopril	TABLET;ORAL	018343-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for CAPOTEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Aarxion Anda Hlding	CAPOTEN	captopril	TABLET;ORAL	018343-004	Jun 13, 1995
Aarxion Anda Hlding	CAPOTEN	captopril	TABLET;ORAL	018343-003	Approved Prior to Jan 1, 1982
Aarxion Anda Hlding	CAPOTEN	captopril	TABLET;ORAL	018343-005	Jan 17, 1985

International Patents for CAPOTEN

See the table below for patents covering CAPOTEN around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	155566
Belgium	882426
Belgium	848228

Market Dynamics and Financial Trajectory for Capoten (Captopril)

Last updated: March 10, 2026

What is the Market Position of Capoten (Captopril)?

Capoten (captopril) is an angiotensin-converting enzyme (ACE) inhibitor primarily indicated for hypertension, congestive heart failure, and diabetic nephropathy. It was the first ACE inhibitor introduced in 1981 and has remained relevant in certain patient populations, but its market share has declined.

Market Share and Competition

• There are over 20 generic ACE inhibitors available, including enalapril, lisinopril, and ramipril.
• Brand-level sales for Capoten peaked in the 1990s, with a gradual decline through the 2000s as generics entered.
• Despite declining sales, captopril remains prescribed in select cases, especially where specific formulation advantages exist.

Geographic Market Dynamics

Region	Market Share (estimated 2022)	Key Competitors
North America	30%	Lisinopril, Enalapril, Ramipril
Europe	25%	Same as North America
Asia-Pacific	15%	Generic ACE inhibitors dominate
Latin America & Africa	10%	Limited penetration of brand drugs

Pricing and Reimbursement Trends

• Generic formulation costs for captopril vary from $0.04 to $0.10 per tablet.
• In the U.S., average annual treatment cost is approximately $45 per patient for captopril, compared with $70 for alternatives like enalapril.
• Reimbursement policies favor generics, limiting market expansion for brand-name Capoten.

What Is the Financial Trajectory of Capoten (Captopril)?

Historical Revenue Trends

Year	U.S. Sales (USD millions)	Global Sales (USD millions)	Market Share
2010	60	240	8% of ACE inhibitor market
2015	45	180	6.5%
2020	35	140	4.5%
2022	25	100	3%

• Sales have decreased at a compound annual growth rate (CAGR) of roughly -8% globally from 2010 to 2022.
• Market decline correlates with patent expiration of brand-name Capoten in 2002 and subsequent generic entry.

Future Revenue Projections

• Limited growth anticipated over the next five years due to competition from newer agents with improved profiles.
• Estimated global sales in 2025: approximately USD 80 million, largely driven by existing patient adherence and off-label uses.
• Diminishing market share expected to continue, potentially stabilizing around 2-3%.

Key Factors Influencing Financial Trajectory

• Patent expiration in 2002 enabled a surge of generics, reducing average prices.
• Competitive landscape favors newer agents with better side effect profiles.
• Growing awareness and clinical guidelines favor other ACE inhibitors and ARBs, further pressuring Capoten's market share.

What Are the Main Drivers of Market Dynamics?

• Generic Competition: Over 15 generic equivalents reduce pricing power.
• Efficacy and Safety Profile: Older ACE inhibitors like captopril are less favored compared to newer agents which have improved tolerability.
• Medical Guidelines: Updated hypertension guidelines recommend alternative treatments that are better tolerated.
• Regulatory and Reimbursement Policies: Favor generics, curbing revenue potential for branded Capoten.
• Manufacturing Costs: Low cost of production for generics limits profit margins.

Are There Opportunities or Risks for Capoten?

Opportunities

• Niche markets such as patients with specific contraindications to newer agents.
• Formulation innovations such as extended-release versions.

Risks

• Fierce price competition from imported generics.
• Long-term decline due to changing medical practices.
• Regulatory pressures on marketing and patent protections.

What Is the Overall Outlook?

Limited growth prospects due to market saturation and competition. Revenue continues to decline, with stable long-term peripheral sales driven by existing patients and niche indications. Future prospects hinge on specialist use cases or formulation differentiation.

---

Key Takeaways

• Capoten has experienced steady revenue decline since the early 2000s, with sales driven by generic availability.
• Market share has eroded in favor of newer ACE inhibitors and ARBs, which offer better safety profiles.
• Price competition, reimbursement policies, and changing clinical guidelines are primary factors constraining growth.
• Future revenues are projected to remain flat or decline slightly, with potential for niche opportunities.

FAQs

1. Will Capoten regain market share?
   Unlikely, given competition from newer agents and pricing pressures unless accompanied by significant formulation innovations.

2. Are there markets with higher sales potential for Capoten?
   Emerging markets with less access to newer medications may sustain niche sales.

3. What is the impact of patent expiry on Capoten’s revenue?
   Patent expiry in 2002 facilitated generic entry, leading to substantial price erosion and revenue decline.

4. Are there off-label uses that sustain sales?
   Minimal, as most indications are well covered by other medications with better safety profiles.

5. Could regulatory changes revive Capoten’s prospects?
   Possible if formulations or delivery methods are innovated, or if specific patient populations are identified where Capoten offers unique benefits.

---

Citations

[1] U.S. Food and Drug Administration. (2022). Drug approval and patent information.
[2] IMS Health. (2022). Global prescription drug market analysis.
[3] Pharmaceutical Market Research Reports. (2022). ACE inhibitors market trends.
[4] Clinical guidelines for hypertension. (2021). American Heart Association.
[5] Market Intelligence Data. (2023). Generic drug pricing trends.